Poxel - Pharmaceutical Company set-up to find innovative solutions for metabolic diseases management with a primary focus on type 2 diabetes

Scientific publications

  • V. Pirags, H. Lebovitz and P. Fouqueray. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients Diabetes, Obesity and Metabolism Volume 14, Issue 9, September 2012, Pages: 852-85
  • Fouqueray and al., The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy Poster #1004-P, American Diabetes Association 72nd meeting, 8-12 June 2012, Philadelphia, USA
    Download the poster
  • P. Fouqueray, X. Leverve (in memoriam), Eric Fontaine, Mathurin Baquié, Claes Wolheim, Harold Lebovitz and Sophie Bozec Imeglimin, A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes, Journal of Diabetes and Metabolism, Volume 2, Issue 4 ISSN: 2155-6156, May 2011
    Read the issue
  • Pirags et al., Imeglimin, a novel glimin oral anti-diabetic, exhibits good glycemic control in Type 2 diabetic patients.
    Poster exhibited at the European Meeting for the Study of Diabetes, Stockholm, September 2010 (PS080, Poster 884)
    Download the poster
  • Fossati L, Dechaume R, Hardillier E, Chevillon D, Prevost C, Bolze S and Maubon N. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int J Pharm. 2008 Aug 6;360(1-2):148-55. Epub 2008 Apr 29
  • Maubon N, Le Vee M, Fossati L, Audry M, Le Ferrec E, Bolze S, Fardel O. Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol. 2007 Dec;21(6):659-63.
  • Hallakou S., Doaré L., Foufelle F., Kergoat M., Guerre-Millo M., Berthault MF., Dugail I., MorinLo KM., Zhang J., Sun Y., Morelli B., Lan Y., Lauder S., Brunkhorst B., Webster G., Hallakou- Bozec S., Doaré L. and Gillies SD. Engineering a pharmacologically superior form of leptin for the treatment of obesity. Protein Eng. Des. Sel. 2005, 18: 1-10
  • Bienvenu G., Seurin D., Grellier P., Baudrimont M., Monget P., Le Bouc Y. and Babajko S. Insulin-like Growth Factor Binding Protein-6 transgenic mice : post-natal growth, brain development and reproduction abnormalities. Endocrinology. 2004 ; 145(5) : 2412-2420.
  • Howlett H, Porte F, Allavoine T, Kuhn T and Nicholson G. The development of an oral antidiabetic tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Current medical research and Opinion 2003, 19 (3) : 218-225
  • Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, Hulot T. Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos. 2002 Apr;30(4):404-13
  • Grellier P., de Galle B. and Babajko S. Expression of insulin-like growth factor binding protein- 6 complementary DNA alters neuroblastoma cell growth. Cancer Res. 1998 ; 58 : 1670-1676.
  • Hallakou S., Foufelle F., Doaré L., Kergoat M., and Ferré P. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat explained by local adipocyte differentiation. Diabetologia 1998; 41: 963-8
  • J., Auwerx J., Ferré P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997, 46: 1393-9
  • Grellier P., Sabbah M., Fouqueray B., Woodruff K., Yee D., Abboud HA. and Abboud SL. Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP-3 in glomerular mesangial cells. Kidney Int. 1996 ; 49 : 1071-1078.
  • Grellier P., Chanson P., Casadevall N., Abboud SL. and Schaison G. Remission of polycythemia vera after surgical cure of acromegaly. Ann. Int. Med. 1996 ; 124 : 495-496.

Sitemap | Legal
© Poxel SA